Evaluation of safety and early efficacy of AAV gene therapy in mouse models of vanishing white matter disease.
Herstine JA, Chang PK, Chornyy S, Stevenson TJ, Sunshine AC, Nokhrina K, Rediger J, Wentz J, Vetter TA, Scholl E, Holaway C, Pyne NK, Bratasz A, Yeoh S, Flanigan KM, Bonkowsky JL, Bradbury AM.
Herstine JA, et al. Among authors: scholl e.
Mol Ther. 2024 Jun 5;32(6):1701-1720. doi: 10.1016/j.ymthe.2024.03.034. Epub 2024 Mar 27.
Mol Ther. 2024.
PMID: 38549375